These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24350530)

  • 1. Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
    Dossabhoy NR; McRight S; Sangha B; Khan S; Adgeh C
    J La State Med Soc; 2013; 165(5):283-5. PubMed ID: 24350530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
    Singh A; Sarkar SR; Gaber LW; Perazella MA
    Am J Kidney Dis; 2007 Jan; 49(1):153-7. PubMed ID: 17185156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unusual complication of treatment with orlistat.
    Karamadoukis L; Shivashankar GH; Ludeman L; Williams AJ
    Clin Nephrol; 2009 Apr; 71(4):430-2. PubMed ID: 19356376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orlistat and calcium oxalate crystalluria: an association that needs consideration.
    Ahmed MH
    Ren Fail; 2010; 32(8):1019-21. PubMed ID: 20722574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-the-counter weight loss with orlistat?
    Drug Ther Bull; 2009 Nov; 47(11):125-7. PubMed ID: 19887686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
    Buysschaert B; Aydin S; Morelle J; Hermans MP; Jadoul M; Demoulin N
    Diabetes Metab; 2016 Feb; 42(1):62-4. PubMed ID: 26454353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
    Solomon LR; Nixon AC; Ogden L; Nair B
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29133578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
    Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
    Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.
    Kwan TK; Chadban SJ; McKenzie PR; Saunders JR
    Nephrology (Carlton); 2013 Mar; 18(3):241-2. PubMed ID: 23432752
    [No Abstract]   [Full Text] [Related]  

  • 11. Orlistat: hepatitis and oxalate nephropathy.
    Prescrire Int; 2012 Mar; 21(125):71. PubMed ID: 22428191
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
    J Pharm Belg; 2009 Jun; (2):67-8. PubMed ID: 19739531
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?
    Karamadoukis L; Ludeman L; Williams AJ
    Nephrol Dial Transplant; 2008 May; 23(5):1778-9. PubMed ID: 18272781
    [No Abstract]   [Full Text] [Related]  

  • 14. Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders.
    Prescrire Int; 2010 Jun; 19(107):125. PubMed ID: 20740721
    [No Abstract]   [Full Text] [Related]  

  • 15. Orlistat-induced fulminant hepatic failure.
    Sall D; Wang J; Rashkin M; Welch M; Droege C; Schauer D
    Clin Obes; 2014 Dec; 4(6):342-7. PubMed ID: 25826164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report.
    Napier S; Thomas M
    Nutr J; 2006 Aug; 5():19. PubMed ID: 16938137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat without a prescription. The SPC now contains more situations where patients are advised to consult a doctor.
    Prescrire Int; 2010 Nov; 19(110):250. PubMed ID: 21287716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat: a second look. At best, a minor adjunct to dietary measures.
    Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.